Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603616 · ClinicalTrials.gov registry record · Phase 2
Induction of Clinical Response Using Rifaximin in Crohn's Disease
A Phase 2 study of Crohn's Disease, sponsored by Scott Lee.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00603616 is a Phase 2 study of Crohn's Disease that has completed, run by Scott Lee. The registered enrollment target is 36 participants, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00603616, a Phase 2 study of Crohn's Disease, has completed, sponsored by Scott Lee.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
Antibiotics have been used to treat Crohn's disease symptoms with the best studied antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is very poorly absorbed and over 97% of the drug taken orally is excreted in the feces. The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for the treatment of moderate to severe symptoms of Crohn's Disease.
Conditions Studied
Interventions
- DRUG Rifaximin
- DRUG Placebo Comparator
Study Locations (1)
Washington
- University of Washington Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-11 |
| Est. Completion | 2020-11-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00603616
The ClinicalTrials.gov registry entry for NCT00603616 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (98% lower). The listed sponsor is Scott Lee, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Rifaximin is the first listed.
NCT00603616 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00603616 about?
NCT00603616 is a clinical study titled "Induction of Clinical Response Using Rifaximin in Crohn's Disease". Antibiotics have been used to treat Crohn's disease symptoms with the best studied antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is very poorly absorbed and over 97% o...
What is the current status of trial NCT00603616?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2008-11. Estimated completion is 2020-11-03.
What conditions does trial NCT00603616 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT00603616?
The interventions under investigation include: Rifaximin (DRUG), Placebo Comparator (DRUG).
Who is sponsoring clinical trial NCT00603616?
This trial is sponsored by Scott Lee, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00603616 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
RECRUITING · Phase 2
-
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.